Результаты поиска

Selected Parameters of Bone Turnover in Neuroendocrine Tumors-A Potential Clinical Use?

BackgroundCurrently, there are no effective markers to diagnose and monitor patients with neuroendocrine tumors (NETs). The aim of this study was to assess bone metabolism based on selected markers of bone turnover: OST, OPG, and IGFBP-3, in both the group of patients with NETs and the control group. Associations with selected sociodemographic, biochemical, and clinicopathological characteristics were examined. We also evaluated any potential associations between these markers and selected biochemical markers of NETs commonly used in clinical practice.MethodsThe study group included 60 patient

Совпадение в полном тексте источника
… However, in acromegaly, in which treatment with a long-acting somatostatin analog (octreotide) is used, a reduction in OST via lowered IGF-1 levels was observed [ 33 ]. … Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: Effects of long-term octreotide treatment Calcif. Tissue Int. 1993 52 188 191 10.1007/BF00298716 8481830 34. Tsubochi H. Endo S. Oda Y. Dobashi Y. …

Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT).

Cancer patients have an increased risk of developing venous thromboembolic events. Anticoagulation management includes prophylactic or therapeutic doses of low molecular weight heparins (LMWHs) or direct oral anticoagulants (DOACs). However, the management of thrombosis in patients with cancer is complex due to various individual and disease-related factors, including drug-drug interactions (DDIs). Furthermore, DDIs may impact both, cancer and venous thrombosis, treatment effectiveness and safety; their relevance is highlighted by the advances in cancer therapeutics. Given that these new oncol

Совпадение в полном тексте источника
… inhibitor Inhibitor 98-99% CML Nilotinib Moderate inhibitor and substrate Inhibitor and substrate Inhibitor and substrate 98% Head&Neck, Lung Nintedanib No Strong inhibitor and substrate No 97.8% Bladder, Colorectal, Gastric, Head&Neck, Liver, Lung, Oesophagus, Melanoma Nivolumab No No No No Thymoma, NETs Octreotide … Nilotinib | Moderate inhibitor and substrate | Inhibitor and substrate | Inhibitor and substrate | 98% Head&Neck, Lung | Nintedanib | No | Strong inhibitor and substrate | No | 97.8% Bladder, Colorectal, Gastric, Head&Neck, Liver, Lung, Oesophagus, Melanoma | Nivolumab | No | No | No | No Thymoma, NETs | Octreotide …

Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Other treatments included budesonide in 9 and octreotide in 2. Total parenteral nutrition (TPN) was utilized in 9 (47%) patients, with clinical benefit seen in 7 patients. …

Infection related membranoproliferative glomerulonephritis secondary to anaplasmosis: A case report.

BACKGROUND: Anaplasmosis is a tick-borne disease with a range of clinical manifestations, from a flu-like illness with fever and myalgias to a severe systemic disease with multisystem organ failure. Although renal involvement is not a common presentation, there have been few cases reporting acute kidney injury from Anaplasmosis. CASE SUMMARY: We present a 55-year-old female with anaplasmosis who developed acute kidney injury due to membranoproliferative glomerulonephritis (MPGN). The patient originally presented with cough and shortness of breath. She was admitted to the hospital with a diagn

Совпадение в полном тексте источника
… She received albumin, midodrine, and octreotide. OUTCOME AND FOLLOW-UP On day 5, she underwent paracentesis due to underlying alcoholic liver cirrhosis with ascites. The paracentesis cultures were negative. …

Keyword Index for Volume 95

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… 247 NGF 322 nitroreductase 1212 NK105 601 non-Hodgkin's lymphoma 1598 non-small cell lung cancer (NSCLC) 470, 717, 817, 822, 966, 998, 1142, 1653 nonsteroidal anti-inflammatory drugs 363, 1277 normal breast 515 Norway 366 novel therapy 961 NQO1 1229 NQO2 1229 nutritional assessment 431 octreotide …

Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study.

Background: With the increasing disease burden of cancer worldwide, more and more anticancer drugs have been approved in many countries, and the results of budget impact analyses (BIAs) have become important evidence for related reimbursement decisions. Objectives: We systematically reviewed whether BIAs for anticancer drugs consider the scope of costs rationally and compared the results of different cost scopes to provide suggestions for future analyses and decision-making. Methods: Eligible BIAs published in PubMed, Embase, Web of Science, and the Cochrane Library from 2016 to 2021 were iden

Совпадение в полном тексте источника
… . | Drug costs | PD-L1 testing, Radiology (CT, MR), Pulmonologist/ oncologist/nurse, pharmacy and traveling expenses | / | No Ortendahl ( 66 ) | 2017 | US | Lanreotide Or Octreotide | Model | Hospital | Hospitals' budgets | Patients with GEP-NETs | 1 year | Substitution | Lanreotide+ Octreotide | Calculating …

Molecular imaging in oncology: Common PET/CT radiopharmaceuticals and applications.

PET/CT is a commonly used modality in cancer imaging, as it can help in diagnosis, staging and assessment of treatment response in many cancer types. A better understanding of the tumor microenvironment and identification of multiple selective targets are promoting further investigation into different radiotracers for diagnosis and therapy. In the past few decades many radiopharmaceuticals have emerged for specific oncologic indications providing superior detection rate than some morphologic modalities. The purpose of this review is to provide an update on the most current radiopharmaceuticals

Совпадение в полном тексте источника
… Mechanism of action Somatostatin receptor (SSTR) is highly expressed in the well-differentiated neuroendocrine tumor (NET) as well as normal organs including brain, peripheral neurons, endocrine pancreas, and gastrointestinal tracts. 68 Ga-DOTA-conjugated peptides including [ 68 Ga-DOTA 0 -Tyr 3 ]octreotide … ( 68 Ga-DOTA-TOC), [ 68 Ga-DOTA 0 -1NaI 3 ]octreotide ( 68 GaDOTA-NOC), and [ 68 Ga-DOTA 0 -Tyr 3 ]octreotate ( 68 GaDOTA-TATE), as well as 64 Cu analogs are radiolabeled somatostatin analogs that specifically bind to SSTR and can be used for PET imaging. …

Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium.

X-linked hypophosphatemia (XLH) is the most common genetic form of hypophosphatemic rickets and osteomalacia. In this disease, mutations in the PHEX gene lead to elevated levels of the hormone fibroblast growth factor 23 (FGF23), resulting in renal phosphate wasting and impaired skeletal and dental mineralization. Recently, international guidelines for the diagnosis and treatment of this condition have been published. However, more specific recommendations are needed to provide guidance at the national level, considering resource availability and health economic aspects. A national multidiscip

Совпадение в полном тексте источника
… Matrix extracellular phosphoglycoprotein (MEPE) correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgery in hypophosphatemic linear sebaceous nevus syndrome. Am J Med Genet A (2008) 146A(16):2164–8. 10.1002/ajmg.a.32395 75. … Breer S, Brunkhorst T, Beil FT, Peldschus K, Heiland M, Klutmann S, et al. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT. Bone (2014) 64:222–7. 10.1016/j.bone.2014.04.016 103. …

Timeline of Translational Formulation Technologies for Cancer Therapy: Successes, Failures, and Lessons Learned Therefrom.

Over the past few decades, the field of cancer therapy has seen a significant change in the way in which formulations are designed and developed, resulting in more efficient products that allow us to ultimately achieve improved drug bioavailability, efficacy, and safety. However, although many formulations have entered the market, many others have fallen by the wayside leaving the scientific community with several lessons to learn. The successes (and failures) achieved with formulations that have been approved in Europe and/or by the FDA for the three major types of cancer therapy (peptide-bas

Совпадение в полном тексте источника
… | IV, IM | 2 weeks | Lymphoblastic leukemia | 1994 | Active Solid implant | Inhibition of gonadotropin secretion | Buserelin acetate | Suprefact Depot | SC | 2–3 months | Prostate cancer | 1996 | Active Microspheres | Inhibition of secretion of peptides from the endocrine gastrointestinal system | Octreotide … The third microsphere-based formulation is Sandostatin LAR ® , an intramuscular long-acting dosage form that encapsulates octreotide acetate within PLGA (55:45 lactic/glycolic molar ratio) microspheres of about 50 μm in size. …

Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis.

Immunoglobulin light chain (AL) amyloidosis is a disorder of clonal plasma cells characterized by deposition of amyloid fibrils in a variety of tissues, leading to end-organ injury. Renal or cardiac involvement is most common, though any organ outside the central nervous system can develop amyloid deposition, and symptomatic presentations may consequently vary. The variability and subtlety of initial clinical presentations may contribute to delayed diagnoses, and organ involvement is often quite advanced and symptomatic by the time a diagnosis is established. Additionally, while organ function

Совпадение в полном тексте источника
… For diarrhea related to malabsorption, octreotide may provide additional benefit. …

Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome.

BackgroundThis article about the emerging field of cardio-oncology highlights typical side effects of oncological therapies in the cardiovascular system, cardiovascular complications of malignancies itself, and potential preventive or therapeutic modalities.MethodsWe performed a selective literature search in PubMed until September 2016.ResultsCardiovascular events in cancer patients can be frequently attributed to oncological therapies or to the underlying malignancy itself. Furthermore, many patients with cancer have pre-existing cardiovascular diseases that can be aggravated by the malignan

Совпадение в полном тексте источника
… Shen C Shih YC Xu Y Yao JC Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis Cancer 2014 120 13 2039 2049 10.1002/cncr.28653 24676892 53. …

Bony metastases: assessing response to therapy with whole-body diffusion MRI.

There are no universally accepted methods for assessing tumour response in skeletal sites with metastatic disease; response is assessed by a combination of imaging tests, serum and urine biochemical markers and symptoms assessments. Whole-body diffusion magnetic resonance imaging excels at bone marrow assessments at diagnosis and for therapy evaluations. It can potentially address unmet clinical and pharmaceutical needs for a reliable measure of tumour response. Signal intensity on high b-value images and apparent diffusion coefficient values can be related to underlying biophysical properties

Совпадение в полном тексте источника
… These include [ 18 F]sodium fluoride ([ 18 F]NaF), [ 18 F]fluorodeoxyglucose ([ 18 F]FDG), [ 11 C]/[ 18 F]choline (for prostate cancer), [ 18 F]fluoroestradiol ([ 18 F]FES); for hormone positive breast cancer), 68 Ga-labeled analogues of octreotide (e.g. [ 68 Ga]DOTATOC; for neuroendocrine tumours) [ …

2021 ACMT Annual Scientific Meeting Abstracts-Virtual.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas.

We aimed to elucidate the diagnostic potential of the C-X-C motif chemokine receptor 4 (CXCR4)-directed positron emission tomography (PET) tracer 68Ga-Pentixafor in patients with poorly differentiated neuroendocrine carcinomas (NEC), relative to the established reference standard 18F-FDG PET/computed tomography (CT). In our database, we retrospectively identified 11 treatment-naïve patients with histologically proven NEC, who underwent 18F-FDG and CXCR4-directed PET/CT for staging and therapy planning. The images were analyzed on a per-patient and per-lesion basis and compared to immunohistoch

Совпадение в полном тексте источника
… Van Echteld C.J. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study Theranostics 2016 6 501 510 10.7150/thno.13702 26941843 PMC4775860 5. Strosberg J. El-Haddad G. Wolin E. Hendifar A. …

Первая стадия испытания иополосина I 131 и Dexametasone в пациентах с повторной релапсированной/отправленной миеломой.

Справочная информация/цели: Пациенты, страдающие рецидивом/отторжением множественных миелом (RRMM), имеют плохие результаты в плане выживания и ограниченные возможности лечения. Все более широкое использование многоагентной терапии для более ранних направлений лечения и новых классов лекарственных препаратов, включая целевые агенты BCMA в последующих направлениях терапии, обусловило необходимость в новаторских платформах лечения у пациентов, которые вновь вернулись к этим стандартным подходам к уходу или отстали от них. Иопофосин I 131 a 131iodid (131I)-фосфолипидный спаривание, использующее с

Совпадение в полном тексте источника
… Similarly, 177 Lu-DOTATATE has shown efficacy in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, with the NETTER-1 trial demonstrating marked improvement in progression-free survival compared with high-dose octreotide [ 14 ]. …

Hypercalcemia of Malignancy: Mechanisms and Therapeutic Implications of Concurrently Elevated PTHrP and Calcitriol.

ContextAlthough initially considered rare and associated with solid tumors, concurrent elevations in PTH-related peptide (PTHrP) and calcitriol have been increasingly detected in hypercalcemic patients with a variety of solid and hematologic malignancies. This review discusses the prevalence and pathophysiology and reevaluates the diagnostic and therapeutic implications of PTHrP and calcitriol co-mediated hypercalcemia of malignancy (HCM).Evidence acquisitionWe searched PubMed using multiple combinations of "hypercalcemia of malignancy," PTHrP," "calcitriol," "combined causes," and "concurrent

Совпадение в полном тексте источника
… Y | Y (after second cycle) | NR a Solid tumors Seminoma | 35/M | Chemotherapy (bleomycin/ etoposide/ cisplatin), 4 cycles | NR | Y | Y | 8 months a | 8 months | Y | [ 19 ] Pancreatic neuroendocrine tumor | 59/M | Pamidronate | 90 | N | N | NA | 57 months | Y | [ 18 ] Zoledronate | 8 mg | N | N | NA Octreotide …

The insulin-like growth factor system and its receptors: A potential novel anticancer target.

The current generation of novel anticancer therapies that are in preclinical and clinical development are based on exploiting our increasing understanding of the molecular and cellular basis of cancer development and progression. Accelerated rates of cell division and proliferation have been postulated to predispose to the development of malignant disease. The insulin-like growth factor (IGF) signaling system has an important physiological role in regulating cellular proliferation and apoptosis. This function has led to considerable interest in its relevance to neoplasia over the last decade.

Совпадение в полном тексте источника
… Disrupting its action with the use of therapeutics such as somatostatin analogues (for example, octreotide) or GH releasing hormone antagonists has shown both anticancer efficacy in preclinical models and a reduction in plasma IGFI levels ( Pollak and Schally 1998 ; Letsch et al 2003 ). …

Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.

Prostate cancer (PCa) is the second most common cancer in men. Common treatments include active surveillance, surgery, or radiation. Androgen deprivation therapy and chemotherapy are usually reserved for advanced disease or biochemical recurrence, such as castration-resistant prostate cancer (CRPC), but they are not considered curative because PCa cells eventually develop drug resistance. The latter is achieved through various cellular mechanisms that ultimately circumvent the pharmaceutical's mode of action. The need for novel therapeutic approaches is necessary under these circumstances. An

Совпадение в полном тексте источника
… . | NCT00330759 | III | 1 June 2006 | 1779 | Completed | Denosumab + zoledronic acid Somatostatin analogue | Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced PCa Patients | NCT00166725 | II | 1 February 2004 | 40 | Completed | Octreotide acetate Anticoagulant | Standard …

Inpatient Medicine

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Metronomic chemotherapy.

Toxic effects and chemoresistance are major hurdles in chemotherapy and to avoid these problems caused by traditional chemotherapeutic regimens, a new modality of drug administration called "metronomic chemotherapy" has emerged. Such regimen involves the frequent administration of conventional chemotherapeutic agents at very low doses to target activated endothelial cells in tumors, the advantages of which include minimal adverse effects and a rare chance of developing acquired drug resistance. Previously it was thought that they act by targeting angiogenesis, but recently additional mechanism

Совпадение в полном тексте источника
… Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma Neth J Med 2001 59 50 6 11476912 10.1016/s0300-2977(01)00140-1 28 Brizzi MP Berruti A Ferrero A Milanesi E Volante M Castiglione F Continuous 5-fluorouracil infusion plus long acting octreotide …